Novartis: Sandoz US – Updated Formulary wins for SYMJEPI

Effective immediately, over 60% of commercially insured people in the US now have access to SYMJEPI (epinephrine) 0.3 mg and 0.15 mg Injections through National and Regional Payers.

https://www.marketscreener.com/NOVARTIS-9364983/news/Novartis-Sandoz-US-IMPORTANT-UPDATE-Formulary-wins-for-SYMJEPI-29041233/